Company
Global biopharmaceutical company headquartered in New York, developing and selling oncology, hematology, immunology and cardiovascular medicines.
Joint Economic Committee Democrats say Trump's pharma stock reached up to $56.2 million by the end of 2025, from up to $1.7 million in 2024. Up to $39.1 million of it is in drugmakers that benefited from Medicare negotiation exemptions, and the White House denies any conflict.
Reality
AstraZeneca will pay insitro $40 million up front, with up to about $1.46 billion in milestones to follow, for liver and heart targets. At 2.7% of the disclosed total, the upfront leaves most of the value tied to targets insitro has yet to deliver.
Perspective Coverage
5 publishersReality
Lotte Biologics will make drug substance for several Alvotech antibody biosimilars at its 40,000-liter plant in Syracuse, New York. Alvotech's CEO said its network now covers a decade of pipeline demand, so more work for Lotte depends on how many Alvotech products launch.
Reality
The company's head of life sciences told Reuters that real lab work is still the final test in biology. Anthropic has not said which experiments the lab is running, and it has yet to run a clinical trial.
Perspective Coverage
5 publishersReality
Orum halted an earlier antibody-degrader conjugate in April last year after a death and unexplained liver toxicity. The candidate Bristol Myers is testing in leukemia sits on the same platform, and a second in-house candidate uses the same degrader.
Reality
MassBio's annual snapshot pairs a recovering VC, IPO and M&A market with a 39% fall in seed capital, a 6% drop in NIH awards and 3,605 lost jobs.
Reality